Kornimate/medical-research-clean huggingface dataset:
comparison of treadmill and whole body vibration training in children with attention deficit hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder

Summary: it is reported in the literature that children with attention deficit hyperactivity disorder (adhd) may have executive function deficits, impaired social functions, emotional dysregulation, behavioral disorders and motor impairments. furthermore, studies have shown that exercise, such as acute and chronic aerobic exercises and acute whole body vibration training, improves executive functions and motor abilities and so it is hypothesized that exercise may have a potential or additional treatment option for children with adhd. neurobiological researches have already proven the effects on brain changes during exercise and in the case of adhd, increasing levels of serotonin, dopamine, and norepinephrine within the front striatal lobes of the brain were highlighted when discussing the effects on this neurodevelopmental disorder. the literature emphasizes the importance of physical activity in children with adhd, but there is no clarity regarding the frequency, intensity or duration of the exercise. thus, the aim of this study was to investigate and compare the effects of treadmill training as an aerobic exercise and whole body vibration training on executive functions and balance in children with adhd.


Eligibility criteria:
inclusion criteria: * adhd diagnosis (previously not taking or not taking medication for adhd) * being going to primary school exclusion criteria: * having a chronic and serious medical condition * seizure-like neurological impairment * autism spectrum disorder, vision, speech, hearing problems

Keywords: treadmill training whole body vibration training
quality of diet in preschool population

Conditions: Feeding and Eating Disorders of Childhood

Summary: childhood obesity is a problem of high prevalence and repercussions in adulthood. it is mostly due to inadequate life habits, modifiable through preventive strategies. the objective was to evaluate in the medium term the effectiveness of an intervention on adherence to the mediterranean diet pattern in preschoolers. method: community trial with two groups, in children between 3-5 years. the experimental group conducted a school garden and the usual contents on human body and health were taught in the control. two schools were selected by cluster sampling, whose first unit of randomization were the educational areas followed by schools. the adaptation to the mediterranean diet pattern was evaluated using the kidmed questionnaire and weight, height, bmi and sociodemographic variables were controlled.


Eligibility criteria:
inclusion criteria: * age between 3 and 5 years * oral comprehension of spanish. exclusion criteria: * existence of language barriers in parents defined as not understanding spoken or written spanish. * treatment with glucocorticoids. * having chronic diseases that could interfere with somatometry.

Keywords: nutritional status child nutrition sciences nutrition therapy nutrition assessment diet, food, and nutrition
evaluating the performance of ai in evaluating breast mri performed with dose reduction

Conditions: Breast Benign Tumor; Breast Malignant Tumor

Summary: the purpose of this study is to evaluate the ability of ai to correctly aid in characterization of benign and malignant lesions even when a low dose of gadolinium is administered. this study is relevant for several reasons, most notably being the reduction of mri dose and decreased gadolinium deposition in the brain. in addition, use of ai may provide increased sensitivity and specificity for the radiologist evaluating a breast mri exam. half of the population will have benign pathologies and the other half will have malignant pathologies.

the study involves each patient presenting for an initial mri with a regular dose of gadolinium and then presenting at least 48 hours after (no less than 14 days later) for a ¼ dose (see below regarding dosing) gadolinium mri exam. both exams will be performed on a 1.5 tesla magnet. both exams will include a full protocol. the full dose contrast exam will be read as standard protocol. all images will be anonymized. images from the reduced dose study will be collected and an ai algorithm applied. all three anonymized data sets (regular dose, low dose, and ai algorithm applied to low dose) will be provided to the readers. readers will be three attending radiologists specializing in breast imaging. exams will be scored on quality, background parenchymal enhancement (bpe), and lesion conspicuity. enhancing lesions will be identified and characterized by the radiologists in a document provided.

Eligibility criteria:
inclusion criteria for breast cancer patients: * female patient between ≥ 18 years old and ≤ 99 years old * patients with newly diagnosed primary breast cancer * patient able and willing to participate in the trial inclusion criteria for non-malignant indications: * female patients between ≥ 18 years old and ≤ 99 years old * be referred for mri for non-malignant indications (screening or birads 3) * patients have had prior exam with known enhancing mass, nonmass enhancement, or focus/foci. exclusion criteria: * non-female patients * patients \< 18 years old * women who are lactating or pregnant * patients with recurrent breast cancer * patients who have already received neoadjuvant chemotherapy * unable to lie still on the imaging table for one (1) hour * patients that are unable to undergo mri evaluation for reasons specific to mri
tamibarotene plus azacitidine in participants with newly diagnosed rara-positive higher-risk myelodysplastic syndrome

Conditions: Myelodysplastic Syndromes

Summary: this study compares the efficacy of tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are retinoic acid receptor alpha (rara) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (hr-mds), and who have not received treatment for this diagnosis. the primary goal of the study is to compare the complete remission rate between the two treatment arms.

a subset of participants have mds characterized by an overexpression of the rara gene. a blood test will be used to identify participants with rara-positive mds. assessment of the rara biomarker for study eligibility will be done by collection of blood samples from potential study participants at the pre-screening visit and testing at a central laboratory. participants who meet eligibility requirements will be randomized 2:1 to receive either tamibarotene plus azacitidine or placebo plus azacitidine.

Eligibility criteria:
key inclusion criteria: * participants must be rara-positive based on the investigational assay. * participants must be newly diagnosed with hr-mds as follows: * diagnosis of mds according to the world health organization (who) classification and classified by the revised international prognostic scoring system (ipss r) risk category as very high, high, or intermediate risk. * participants must have eastern cooperative oncology group (ecog) performance status of ≤2. key exclusion criteria: * participants are suitable for and agree to undergo allogeneic hematopoietic stem cell transplant (hsct) at the time of screening. * participants who need treatment prior to stem cell transplant can receive treatment on this study and stop the study treatment when they are ready to proceed to transplant. * participants who received prior treatment for mds with any hypomethylating agent, lenalidomide, chemotherapy or allogeneic hsct.

Keywords: higher-risk retinoic acid receptor alpha (rara) positive newly diagnosed myelodysplastic syndromes
changes in the diameter of retinal vessels after remote ischemic conditioning

Conditions: Retinal Artery Occlusion; Retinal Vein Occlusion

Summary: remote ischemic conditioning (ric) is a therapeutic strategy for protecting organs or tissue against the detrimental effects of acute ischemia-reperfusion injury. it remains unknown whether this can be used in retinal vascular occlusive diseases. the purpose of the present study is to examine whether the autoregulation of retinal vessel diameters in normal persons change after remote ischemic conditioning.


Eligibility criteria:
inclusion criteria: * normal persons exclusion criteria: * present or previous eye disease * use of medications except anti-conceptive * epilepsy * pregnancy or lactation
exploring liver and muscle fat content using mri

Conditions: Polycystic Ovary Syndrome

Summary: the aim of our study was to compare the difference of fatty infiltration in liver and muscle using magnetic resonance imaging (mri) between overweight as well as obese polycystic ovary syndrome (pcos) cases and body mass index (bmi)-matched women without pcos, identifying the possible influence factors.


Eligibility criteria:
inclusion criteria: (1) subjects with a body mass index (bmi) ≥ 24 kg/m2; (2) subjects aged between 18 and 40 years; (3) subjects who had not received any prescription or non-prescription drugs that affect insulin sensitivity or ovarian function, including hormonal contraceptives and metformin, within three months before the trial; (4) pcos diagnosis fulfills the rotterdam 2003 criteria phenotype b with hyperandrogenism (ha) and oligo-/anovulation \[29\]; (5) subjects who had not received medication that impacts lipid metabolism (fibrates, statins, antioxidants and diuretic) in the recent 3 months; (6) subjects who did not intend to become pregnant and use barrier contraception; (7) subjects who did not change their lifestyle, including physical activity and eating habits, during the study period. exclusion criteria: -
anxiety level of child and parents during preoperative anesthesia evaluation

Conditions: Anxiety State; Parent; Child

Summary: 1. appreciation of preoperative anxiety in children is important for the anesthesiologist. 2. several factors defined to effect the anxiety levels preoperatively in children such as , age, previous medical encounters , education level and parental anxiety. 3. this information was tested for turkish children during the preoperative anesthetic evaluation.

1. before the planned surgery all children accompanying parents filled a questionnaire about the demographics, marital status, economical conditions, education level and other diseases and operations in the family. 2. both the parent and child filled state and trait anxiety tests specially prepared for adults spielberger anxiety tests and children defined and validation tests had already been proven. statistical analysis performed for evaluation.

Eligibility criteria:
inclusion criteria: * legible exclusion criteria: * illegible due to lack of education or eye diseases

Keywords: anxiety preoperative
safety and efficacy evaluation of γ-globin reactivated autologous hematopoietic stem cells

Conditions: β Thalassemia Major

Summary: this is a non-randomized, open label, single-dose, phase 1/2 study in up to 12 participants with β-thalassemia major.this study aims to evaluate the safety and efficacy of the treatment with γ-globin reactivated autologous hematopoietic stem cells in subjects with β-thalassemia major.

γ-globin reactivated autologous hematopoietic stem cells will be manufactured using crispr/cas9 gene editing system. subject participation for this study will be 1 year. subjects who enroll in this study will be asked to participate in a subsequent long-term follow up study that will monitor the safety and efficacy of the treatment they receive for up to 15 years post-transplant.

Eligibility criteria:
inclusion criteria: * fully understand and voluntarily sign informed consent. 5-15years old. at least one legal guardian and/or subjects to sign informed consent. * clinically diagnosed as β-thalassemia major, phenotypes including β0β0, β+β0,βeβ0 genotype. * subjects with no affection with ebv, hiv, cmv, tp, hav, hbv and hcv. * subjects body condition eligible for autologous stem cell transplant. exclusion criteria: * subjects acceptable for allogeneic hematopoietic stem cell transplantation and have an available fully matched related donor. * active bacterial, viral, or fungal infection. * treated with erythropoietin prior 3 months. * immediate family member with any known hematological tumor. * subjects with severe psychiatric disorders to be unable to cooperate. * recently diagnosed as malaria. * history of complex autoimmune disease. * persistent aspartate transaminase (ast), alanine transaminase (alt), or total bilirubin value \>3 x the upper limit of normal (uln). * subjects with severe heart, lung and kidney diseases. * with serious iron overload, serum ferritin\>5000mg/ml. * any other condition that would render the subject ineligible for hsct, as determined by the attending transplant physician or investigator. * subjects who are receiving treatment from another clinical study, or have received another gene therapy. * subjects or guardians had resisted the guidance of the attending doctor. * subjects whom the investigators do not consider appropriate for participating in this clinical study.
clinical study of multimodal ablation remodeling immunosensitized pd-1 in the treatment of pancreatic cancer with liver metastasis

Conditions: Pancreatic Cancer

Summary: 1. clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, gender is not limited; 2. newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver; 3. imaging evaluable tumors with safe access to puncture; 4. the number of half liver tumors ≤3 and the size of each tumor ≤3 cm; 5. ecog ps score ≤2 points, expected survival \> 3 months. exclusion criteria: 1. liver function child-pugh grade c, severe jaundice, especially obstructive jaundice; 2. the liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume; 3. expected survival \< 3 months; 4. serious heart, lung, liver and kidney dysfunction and coagulation dysfunction; 5. uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study; 6. refractory ascites, pleural fluid or bad fluid; 7. pregnancy or breastfeeding; 8. the researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.

Keywords: liver metastases
effects of adjunctive lacosamide on mood states and quality of life (qol) in patients with epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to determine the effect of lacosamide on mood and quality of life in people with epilepsy.

lacosamide (lcm) was found in phase 3 studies to have good efficacy and tolerability as adjunctive treatment in adult patients with uncontrolled partial onset seizures, with or without secondary generalization. dose-related adverse drug reactions (adrs) included dizziness, headache and nausea, but the incidence of reported mood symptoms was similar to placebo. the very low incidence of such events, combined with lcm's unique mechanism of action, suggest that lcm has the potential to be among the few anti-epileptic drugs (aeds) without clinically significant mood adrs. the effects of lcm on mood states (i.e., worsening or improvement) have not been examined with standardized measures. in addition, its effects on quality of life (qol) have not been explored, although qol is known to be affected by other aeds. the investigators propose to examine the effects of lcm on mood and qol in a real-world population of adult patients with partial-onset seizures. to the knowledge of the investigators, the proposed study will be the first to examine these domains in a scientifically rigorous fashion in patients treated with lcm. thus, study results will fill a current knowledge gap, and will provide important information to clinicians and patients when considering lcm treatment.

Eligibility criteria:
inclusion criteria: * at least 17 years old * have partial (focal) onset seizures that are not controlled with medication * (lcm group only) lcm is being added to anti-epileptic drug regimen by treating physician exclusion criteria: * have taken lcm in the past. * change in anti-epileptic drugs or their doses in the past 28 days. * have participated in another drug research study in the past 3 months. * have had epilepsy brain surgery, or plan to have epilepsy surgery in the next four months. * have a psychiatric or behavioral condition, which in the opinion of the investigator, could compromise patient's ability to participate in the study. * have a progressive (worsening) disease that affects patients brain and its functions.
phase 2 safety and efficacy evaluation of al8326 in ≥2nd line sclc

Conditions: Small Cell Lung Cancer

Summary: this trial is a phase ii trial designed to evaluate the safety and efficacy of using oral al8326 , a multi-targeted receptor tyrosine kinase inhibitor( tki) , to recurrent, advanced, or metastatic small cell lung cancer (sclc) patients who need ≥2nd line treatment .

this study is designed for two steps: phase 2 optimal biological dose (obd) finding and phase 2 expansion cohort study after obd determination. the phase 2 study aims to find optimal biological dose (obd) initially. patients will be randomized to 3 different dosing groups in obd finding cohorts. each cohort will enroll 6-12 sclc patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. this obd finding cohort will also evaluate the pharmacokinetic profile of al8326. a phase 2 expansion cohort will be continued if a positive clinical result would have been observed after obd determination for 40-60 patients. upon fda's approval the phase 2 expansion cohort clinical study will be further expanded to evaluate the safety and efficacy of al8326 in patients individually with sclc who need = or \>2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

Eligibility criteria:
major inclusion criteria: 1. male or female, 18 years of age or older 2. ecog performance status of 0 or 1 3. histologically or cytologically confirmed sclc 4. have at least 1 lesion that meets the criteria for being measurable, as defined by recist 1.1 5. have a life expectancy of at least 3 months major exclusion criteria: 1. serious, non-healing wound, ulcer or bone fracture 2. major surgical procedure within 28 days or minor surgical procedure performed within 7 days prior to treatment 3. active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels 4. clinically significant cardiovascular disease including uncontrolled hypertension; myocardial infarction or unstable angina within 6 months prior to enrollment; new york heart association (nyha) grade ii or greater congestive heart failure serious cardiac arrhythmia requiring medication; and grade ii or greater peripheral vascular disease 5. hemoptysis within 3 months prior to enrollment 6. concomitant treatment with strong inhibitors or inducers of cyp3a4, cyp2c9 and cyp2c19 within 14 days prior to enrollment and during the study unless there is an emergent or life-threatening medical condition that required it. more information available upon request

Keywords: recurrent small cell lung caner advanced small cell lung cancer metastatic small lung cancer ≥2nd line treatment
4d pet/ct in diagnosing participants with lung and colorectal cancer with liver and lung metastasis

Conditions: Metastatic Malignant Neoplasm in the Liver; Metastatic Malignant Neoplasm in the Lung; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8

Summary: this trial studies how well 4 dimensional (d) positron emission tomography/computed tomography (pet/ct) works in diagnosing participants with lung or colorectal cancer that has spread to the liver and lung. diagnostic procedures, such as pet/ct, may help find and diagnose disease and find out how far the disease has spread. but the motions made by breathing can reduce the image quality of the scan. adjusting the scanner to 4d may allow for more breathing motion may improve the quality of the pet/ct images.

primary objectives: i. study the impact of 4d positron emission tomography/computed tomography (pet/ct) imaging on the evaluation and staging of lung and colorectal cancer. outline: participants undergo 4d pet/ct scan over up to 12 minutes.

Eligibility criteria:
inclusion criteria: * patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study. * patients with suspected lung cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study. exclusion criteria: * patients that cannot tolerate being scanned for an additional 12 minutes with arms above their head will be excluded.
nipe monitoring values during routine pediatric anesthesia

Conditions: Anesthesia; Nociceptive Pain

Summary: description of the standard values and fluctuations of the new nipe index during routine pediatric anesthesia. nipe monitor connected to anesthesia monitor, displays an instantaneous value ranging from 0 to 100. nipe values described at different time points during anesthesia: beginning of induction, intubation, extubation, skin incision, opioid administration, vasopressors or atropine administration, transfusion, volume expansion. in addition, nipe values during hemodynamic events (heart rate or blood pressure increase greater than 20%) will be recorded.


Eligibility criteria:
inclusion criteria: * surgery under general anesthesia * absence of analgesic treatment in the 24 hours before the intervention exclusion criteria: * central or peripheral neuropathy * non sinus arrythmia, pace maker * cardiac surgery * analgesic medication within 24 hours before surgery * anti cholinergic or anti arrythmic chronic medication * opposition of the legal tutor or of the child

Keywords: general anesthesia nociceptive pain monitoring pediatric anesthesia